Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids.

IF 12.8 1区医学 Q1 ONCOLOGY

Journal of Experimental & Clinical Cancer Research Pub Date : 2025-07-02 DOI:10.1186/s13046-025-03437-0

Paloma Navarro, Tatiana P Grazioso, Arantzazu Barquín, Maria Barba, Mónica Yagüe, Carlos Millán, Irene López, Elena Sevillano, Miguel Quiralte, Paloma Fernández, Diego Losada, Eduardo Caleiras, Julia Calzas, Beatriz Jiménez, Sergio Ruiz-Llorente, Juan Justo, Félix Guerrero, Vital Hevia, Raquel Martín, Francisco José Pérez-Rodriguez, Julia Tejerina, Mario Prieto, Paula Comune, Juan Francisco Rodriguez-Moreno, Jesús García-Donás

{"title":"Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids.","authors":"Paloma Navarro, Tatiana P Grazioso, Arantzazu Barquín, Maria Barba, Mónica Yagüe, Carlos Millán, Irene López, Elena Sevillano, Miguel Quiralte, Paloma Fernández, Diego Losada, Eduardo Caleiras, Julia Calzas, Beatriz Jiménez, Sergio Ruiz-Llorente, Juan Justo, Félix Guerrero, Vital Hevia, Raquel Martín, Francisco José Pérez-Rodriguez, Julia Tejerina, Mario Prieto, Paula Comune, Juan Francisco Rodriguez-Moreno, Jesús García-Donás","doi":"10.1186/s13046-025-03437-0","DOIUrl":null,"url":null,"abstract":"Background: 3D-spatial interaction between cancer cells influences tumor behavior, making it essential to replicate tumor structures for predicting patient outcomes.Methods: We collected data from three multicenter prospective studies to evaluate the ability to establish Patient-Derived Organoids (PDOs) from different biological samples and timepoints, correlating their characteristics and drug sensitivity with clinical outcomes.Results: From 184 patients (17 tumor types), 249 samples were collected: 149 (59.8%) from tumor tissue, 61 (24.5%) from peritoneal fluids, 39 (15.7%) from peripheral blood. Success rates for PDO establishment were 39.5%, 34.4%, and 25.6%, respectively. PDOs reproduced pathological and immunohistochemical patterns of source tumors, with pathogenic variants confirmed in 84% (21/25). In a series of 13 baseline and sequential PDOs from 9 patients undergoing treatment, responses to therapy mirrored patient responses during therapy.Conclusions: PDOs preserve tumor features, reflect disease progression, and predict treatment responses, providing valuable models to complement molecular testing in precision medicine.","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"44 1","pages":"182"},"PeriodicalIF":12.8000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12220348/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental & Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13046-025-03437-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: 3D-spatial interaction between cancer cells influences tumor behavior, making it essential to replicate tumor structures for predicting patient outcomes.

Methods: We collected data from three multicenter prospective studies to evaluate the ability to establish Patient-Derived Organoids (PDOs) from different biological samples and timepoints, correlating their characteristics and drug sensitivity with clinical outcomes.

Results: From 184 patients (17 tumor types), 249 samples were collected: 149 (59.8%) from tumor tissue, 61 (24.5%) from peritoneal fluids, 39 (15.7%) from peripheral blood. Success rates for PDO establishment were 39.5%, 34.4%, and 25.6%, respectively. PDOs reproduced pathological and immunohistochemical patterns of source tumors, with pathogenic variants confirmed in 84% (21/25). In a series of 13 baseline and sequential PDOs from 9 patients undergoing treatment, responses to therapy mirrored patient responses during therapy.

Conclusions: PDOs preserve tumor features, reflect disease progression, and predict treatment responses, providing valuable models to complement molecular testing in precision medicine.

查看原文本刊更多论文

多中心研究将癌症病例的分子特征和临床结果与患者来源的类器官相关。

背景：癌细胞之间的三维空间相互作用影响肿瘤行为，因此复制肿瘤结构对于预测患者预后至关重要。方法：我们收集了三个多中心前瞻性研究的数据，以评估从不同生物样本和时间点建立患者源性类器官（PDOs）的能力，并将其特征和药物敏感性与临床结果相关联。结果184例患者（17种肿瘤类型）共采集标本249份，其中肿瘤组织标本149份（59.8%），腹膜液标本61份（24.5%），外周血标本39份（15.7%）。建立PDO的成功率分别为39.5%、34.4%和25.6%。PDOs再现了源肿瘤的病理和免疫组织化学模式，84%（21/25）证实了致病性变异。在接受治疗的9名患者的一系列13个基线和顺序pdo中，对治疗的反应反映了患者在治疗期间的反应。结论：PDOs保留了肿瘤特征，反映了疾病进展，并预测了治疗反应，为精准医学中的分子检测提供了有价值的模型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Experimental & Clinical Cancer Research 医学-肿瘤学

CiteScore

18.20

自引率

1.80%

发文量

333

审稿时长

1 months

期刊介绍： The Journal of Experimental & Clinical Cancer Research is an esteemed peer-reviewed publication that focuses on cancer research, encompassing everything from fundamental discoveries to practical applications. We welcome submissions that showcase groundbreaking advancements in the field of cancer research, especially those that bridge the gap between laboratory findings and clinical implementation. Our goal is to foster a deeper understanding of cancer, improve prevention and detection strategies, facilitate accurate diagnosis, and enhance treatment options. We are particularly interested in manuscripts that shed light on the mechanisms behind the development and progression of cancer, including metastasis. Additionally, we encourage submissions that explore molecular alterations or biomarkers that can help predict the efficacy of different treatments or identify drug resistance. Translational research related to targeted therapies, personalized medicine, tumor immunotherapy, and innovative approaches applicable to clinical investigations are also of great interest to us. We provide a platform for the dissemination of large-scale molecular characterizations of human tumors and encourage researchers to share their insights, discoveries, and methodologies with the wider scientific community. By publishing high-quality research articles, reviews, and commentaries, the Journal of Experimental & Clinical Cancer Research strives to contribute to the continuous improvement of cancer care and make a meaningful impact on patients' lives.